Huntington's disease (HD) is a late-onset, autosomal dominant neurodegenerative disease caused by a CAG trinucleotide expansion. The number of repeats on the HD chromosome explains most of the variability in age of onset, but genetic factors other than the HD gene are responsible for part of the residual variance. Based on the role played by the brain derived neurotrophic factor (BDNF) in neurodysfunction and neurodegeneration in HD, we searched for novel polymorphisms in the neuron restrictive silencer element located in the BDNF promoter. Then, the effect of the Val66Met variant in determining age of onset was tested in a large sample of HD carriers by using a multivariate regression approach. The CAG repeat number accounted for 62% of the variance. After correction for the predominant effect of the CAG expansion, no multiple regression model provided evidence of association between the Va166NIet genotype and variation in age-at-onset. Additional studies are warranted to further investigate BDNF as genetic modifier of the HD phenotype

No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease / E. DI MARIA, A. Marasco, M. Tartari, P. Ciotti, G. Abbruzzese, G. Novelli, E. Bellone, E. Cattaneo, P. Mandich. - In: NEUROBIOLOGY OF DISEASE. - ISSN 0969-9961. - 24:2(2006), pp. 274-279. [10.1016/j.nbd.2006.07.002]

No evidence of association between BDNF gene variants and age-at-onset of Huntington's disease

M. Tartari;E. Cattaneo;
2006

Abstract

Huntington's disease (HD) is a late-onset, autosomal dominant neurodegenerative disease caused by a CAG trinucleotide expansion. The number of repeats on the HD chromosome explains most of the variability in age of onset, but genetic factors other than the HD gene are responsible for part of the residual variance. Based on the role played by the brain derived neurotrophic factor (BDNF) in neurodysfunction and neurodegeneration in HD, we searched for novel polymorphisms in the neuron restrictive silencer element located in the BDNF promoter. Then, the effect of the Val66Met variant in determining age of onset was tested in a large sample of HD carriers by using a multivariate regression approach. The CAG repeat number accounted for 62% of the variance. After correction for the predominant effect of the CAG expansion, no multiple regression model provided evidence of association between the Va166NIet genotype and variation in age-at-onset. Additional studies are warranted to further investigate BDNF as genetic modifier of the HD phenotype
Age-at-onset; BDNF; Genetic modifiers; Huntington's disease; Regression analysis; Val66Met polymorphism
Settore BIO/14 - Farmacologia
2006
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WNK-4KMYM1P-1&_user=1080510&_coverDate=11%2F30%2F2006&_rdoc=1&_fmt=&_orig=search&_sort=d&view=c&_acct=C000051355&_version=1&_urlVersion=0&_userid=1080510&md5=5f532726395da3231fa248fbf3b69ee4
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/29802
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 15
social impact